Four years after Sanofi shelled out $125 million for global rights to Biond Biologic | The company is handing back the tumor ...

Gain insights into Recursion Pharmaceuticals' Q4 2024 earnings call. Discover clinical advancements, key partnerships, and strategic plans for 2025.

Novavax on Thursday posted a narrower fourth-quarter loss and said it expects its licensing deal with French drugmaker Sanofi ...

For GSK CEO Emma Walmsley, there was good news and bad news in the company’s annual report. | For GSK CEO Emma Walmsley, ...

AV0328, one of Alopexx’s lead candidates, is a synthetic PNAG vaccine that has completed a phase 1 trial. The biotech is ...

Just nine weeks after UnitedHealthcare CEO Brian Thompson was murdered on a weekday morning on a busy street, the luminaries ...

Sanofi is closer to selling a 50% controlling stake in the consumer health business, Opella to private equity Clayton ...

Sanofi invests in Enveda, reaffirming the industry’s confidence in its AI drug discovery platform and ability to deliver differentiated medicines.

We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Analysts. In this article, we are going ...

The company's molecular research and drug-development platform taps what it calls nature's wisdom to drive the discovery of ...

Enveda gets support from Sanofi to advance AI-driven drug discovery to clinical trials: Boulder, Colorado Friday, February 28, 2025, 16:00 Hrs [IST] Enveda, a leading biotechnolog ...

Robert is currently chief digital officer at the cruise line firm Viking Cruises and will join Sanofi on 15th June. His brief is to drive Sanofi’s digital, data and technology strategy ...